Woodstock Sterile Solutions Appoints First Chief Commercial Officer

Article

Bill Hartzel has been named as Woodstock’s first Chief Commercial Officer.

Woodstock Sterile Solutions, a blow-fill-seal (BFS) contract development and manufacturing organization, announced on April 12, 2021 that it has named Bill Hartzel as its first Chief Commercial Officer.

Hartzel, who will now be responsible for the commercial activities and strategy for the company, previously served as product manager in Medication Delivery Solutions; director of Strategic Execution; regional director of Commercial Operations; and global vice-president of Business Development for Analytical, Respiratory, and Ophthalmics for Catalent, Woodstock’s predecessor, the company said in a press release.

“We are pleased to welcome a dynamic, customer-focused leader like Bill Hartzel to the Woodstock executive team,” said Paul Josephs, CEO, Woodstock, in the press release. “Bill has had an impressive career in the BFS industry and we look forward to him bringing the exceptional business and technical acumen he has demonstrated throughout his career to our leadership team to help us drive sustainable growth for the organization.”

“I am very excited about the opportunities and the potential for growth for Woodstock Sterile Solutions in the pharmaceutical and healthcare industry,” added Hartzel in the press releease. “BFS is an untapped technology and it is primed for growth and expansion—not just in the respiratory and ophthalmic space—but as a sterile delivery platform, where it can help to mitigate the risks involved with sterile manufacturing. The Woodstock business is uniquely positioned to support complex formulations seamlessly from development through commercial production. I look forward to helping Woodstock Sterile Solutions reach its full potential in this market.”

Source: Woodstock

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content